Business
Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)
GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides pharmacists, physicians and patients with
About this update from Wellgistics Health, Inc.
[{"type":"text","content":"GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary side effectForzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) (\"Wellgistics\") , a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced the launch of medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies. Forzet is being launched initially to physicians and pharmacists who prescribe and dispense GLP-1 agonist drugs. Forzet's proprietary formulation has been evaluated in multiple controlled clinical studies, including in patients with Type 2 diabetes, heart failure and COPD in Europe. Forzet will initially be be made available through the Company's affiliated pharmacy and select members of the Wellgistics Pharmacy Network. Forzet is classified as a medical food intended for the dietary management of muscle loss associated with weight loss therapies under physician supervision. Forzet is not an FDA-approved drug, is available over the counter and does not require a prescription. \"Forzet is indicated for the dietary management of muscle loss associated with weight loss therapies,\" said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. \"GLP-1 agonist drugs such as Ozempic®, Wegovy®, Mounjaro® and others are members of the fastest growing class of drugs worldwide because of myriad benefits that result from losing weight. While the benefits of the weight loss associated with GLP-1 agonist therapy can no longer be denied, it remains the case that a significant amount of that weight loss comes from loss of muscle. As such, the Company believes there may be a significant market opportunity for a medical food product that distinguishes itself from dietary supplements by virtue of its extensive clinical data package in sarcopenia associated with other muscle l...